title: FDG in Urologic Malignancies.
abstract: Kidney, bladder, and prostate cancer account for more than one-eighth of new cancer cases worldwide. Imaging in kidney cancer is dominated by computed tomography (CT). Positron emission tomography (PET) imaging of bladder cancer is hampered by the urinary excretion of the most common PET tracer, 18F-fluoro-deoxy-glucose (FDG). PET imaging has been applied more often in prostate cancer. FDG-PET/CT is claimed to have a high frequency of false-negative results in urologic cancers; however, this finding may instead reflect correctly the state of disease being due to slow-growing cancers with a good prognosis and without a need of therapy.
authors.affiliation: Department of Nuclear Medicine, Odense University Hospital, Sønder Boulevard 29, Odense DK-5000, Denmark; Institute of Clinical Research, University of Southern Denmark, Winsløwparken 19, DK-5000, Odense, Denmark. Electronic address: pfhc@rsyd.dk.
authors.forename: Poul Flemming
authors.initials: PF
authors.lastname: Høilund-Carlsen
authors.affiliation: Institute of Clinical Research, University of Southern Denmark, Winsløwparken 19, DK-5000, Odense, Denmark; Department of Urology, Odense University Hospital, Sønder Boulevard 29, Odense DK-5000, Denmark.
authors.forename: Mads Hvid
authors.initials: MH
authors.lastname: Poulsen
authors.affiliation: Department of Nuclear Medicine, Odense University Hospital, Sønder Boulevard 29, Odense DK-5000, Denmark.
authors.forename: Henrik
authors.initials: H
authors.lastname: Petersen
authors.affiliation: Department of Nuclear Medicine, Odense University Hospital, Sønder Boulevard 29, Odense DK-5000, Denmark.
authors.forename: Søren
authors.initials: S
authors.lastname: Hess
authors.affiliation: Institute of Clinical Research, University of Southern Denmark, Winsløwparken 19, DK-5000, Odense, Denmark; Department of Urology, Odense University Hospital, Sønder Boulevard 29, Odense DK-5000, Denmark.
authors.forename: Lars
authors.initials: L
authors.lastname: Lund
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D014571:Urologic Neoplasms / Q000000981:diagnostic imaging*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Bladder cancer; FDG; Prostate cancer; Radionuclide imaging; Renal cancer